This morning the very much awaited for announcement was made: the FDA has granted Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma. The article is below. What this means for patients and their caregivers is new hope. While myeloma is not yet curable, it is treatable, and with each new drug that is approved, patients are able to choose wisely with their doctors which treatment may be the best option for them. Each new drug buys us time and the possibility of longer remissions and better quality of life . . . until someday there is a cure!
Links that may be of interest to you:- Carfilzomib clinical trials
- IMF American Society of Hematology (ASH) Webcasts (check the overview, new agents and relapsed/refractory tabs for presentations about carfilzomib)
- Press release from Onyx Pharmaceuticals announcing the FDA decision to grant Fast Track status to carfilzomib
Leave a comment